Imatinib Mesylate in Treating Patients With Recurrent Meningioma

NCT00045734 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

NIH

Sponsor class

Conditions

Adult Grade I Meningioma
Adult Grade II Meningioma
Adult Grade III Meningioma
Adult Meningeal Hemangiopericytoma
Adult Meningioma
Recurrent Adult Brain Tumor

Interventions

DRUG: imatinib mesylate
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)